Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard D Carvajal

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
American Journal of Clinical Dermatology|February 2, 2019
KIT as an Oncogenic Driver in Melanoma: An Update on Clinical DevelopmentDa Meng, Richard D Carvajal
Expert Opinion on Biological Therapy|February 21, 2013
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapyOmid Hamid, Richard D Carvajal
Current Oncology Reports|July 30, 2020
Novel Approaches to the Systemic Management of Uveal MelanomaShaheer Khan, Richard D Carvajal
Current Oncology Reports|May 17, 2017
Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging TherapiesKimberly M Komatsubara, Richard D Carvajal
Cancer Journal (Sudbury, Mass.)|March 29, 2012
Therapeutic implications of KIT in melanomaMichael A Postow, Richard D Carvajal
Cancer Treatment and Research|November 26, 2015
Treatment of Uveal MelanomaAlexander N Shoushtari, Richard D Carvajal
Hematology/Oncology Clinics of North America|June 2, 2014
Treatments for noncutaneous melanomaDanny N Khalil, Richard D Carvajal
Oncology (Williston Park, N.Y.)|September 25, 2018
Prognostic Value of Low Tumor Burden in Patients With MelanomaAndrew S Poklepovic, Richard D Carvajal
Expert Review of Anticancer Therapy|September 14, 2022
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanomaLanyi Nora Chen, Richard D Carvajal
Melanoma Research|October 12, 2014
GNAQ and GNA11 mutations in uveal melanomaAlexander N Shoushtari, Richard D Carvajal
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
American Journal of Clinical Dermatology|February 2, 2019
KIT as an Oncogenic Driver in Melanoma: An Update on Clinical DevelopmentDa Meng, Richard D Carvajal
Expert Opinion on Biological Therapy|February 21, 2013
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapyOmid Hamid, Richard D Carvajal
Current Oncology Reports|July 30, 2020
Novel Approaches to the Systemic Management of Uveal MelanomaShaheer Khan, Richard D Carvajal
Current Oncology Reports|May 17, 2017
Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging TherapiesKimberly M Komatsubara, Richard D Carvajal
Cancer Journal (Sudbury, Mass.)|March 29, 2012
Therapeutic implications of KIT in melanomaMichael A Postow, Richard D Carvajal
Cancer Treatment and Research|November 26, 2015
Treatment of Uveal MelanomaAlexander N Shoushtari, Richard D Carvajal
Hematology/Oncology Clinics of North America|June 2, 2014
Treatments for noncutaneous melanomaDanny N Khalil, Richard D Carvajal
Oncology (Williston Park, N.Y.)|September 25, 2018
Prognostic Value of Low Tumor Burden in Patients With MelanomaAndrew S Poklepovic, Richard D Carvajal
Expert Review of Anticancer Therapy|September 14, 2022
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanomaLanyi Nora Chen, Richard D Carvajal
Melanoma Research|October 12, 2014
GNAQ and GNA11 mutations in uveal melanomaAlexander N Shoushtari, Richard D Carvajal
Pageof 18